Ocugen, Inc. filed its 10-K on Feb 28, 2022 for the period ending Dec 31, 2021. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.28 USD | +8.47% | -3.03% | +122.61% |
22/04 | Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating | MT |
22/04 | Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+122.61% | 329M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- OCGN Stock
- News Ocugen, Inc.
- Ocugen, Inc. Auditor Raises 'Going Concern' Doubt